KappaMab study (AMaRC 16-01)

A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma.
The primary purpose of this trial is to evaluate the safety and efficacy of KappaMab in combination with Lenalidomide and Dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Project Information

Institution:

Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)

Specialities:

Haematology

Oncology

Other (specify below)

End date:

Suitability:

Parts of research done:

Literature review, Research proposal, Ethics approval, Data collection, Data analysis, Manuscript draft

Positions Available:

Researchers

Statistician

Data Collector

Current Funding:

Haemaologix, Celgene

Website

  • Twitter

Contact

Andrew Spencer

Please fill out the form below to express your interest in this research project. It is free to contact a project owner and express interest in a project. We recommend writing a detailed message regarding why you are interested in the project (e.g. what skills you can bring to the team) or what information you are seeking (e.g. detail regarding the study duration). All information you provide will be shared with the primary researcher, including your contact details. Thank you for your interest in this project.

LINKS:

ABOUT:

Melbourne,

VIC. 3002

Australia

 

0424 730 627

info@theresearchcollab.com

ABN: 77 640 321 295

CONNECT WITH US:

  • Twitter
  • White Facebook Icon
  • White Instagram Icon
  • LinkedIn - White Circle